Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEATrial

Albrecht Kretzschmar(Roche (Switzerland)), David Cunningham(Royal Marsden NHS Foundation Trust), Scott Berry, M. Michael(Peter MacCallum Cancer Centre), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Beatrix Lutiger(Peter MacCallum Cancer Centre), Fernando Rivera(Marqués de Valdecilla University Hospital), M. Mazier(PAREXEL International (France))
Journal of Clinical Oncology
June 20, 2007
10.1200/jco.2007.25.18_suppl.4072
Cited by 19

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k